Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationSentinel · solid tumours on treatment
Sentinel Solid
Tracking ctDNA from repeat blood draws to show whether therapy is working and to catch resistance early.
01Sentinel Solid
Serial ctDNA monitoring for solid tumours
From repeat blood draws, Sentinel Solid tracks ctDNA to show whether therapy is working and to catch molecular progression or resistance early, often before imaging reveals the cancer moving.
Response
Falling ctDNA as an early sign the current therapy is working.
Molecular progression
A rising trend that can precede radiographic progression.
Resistance mutations
New changes that let the cancer escape the current drug, so a switch can be planned in time.
02
The Sentinel alert workflow
- Step 1Red flag
A rising ctDNA trend or a new resistance mutation on a scheduled draw.
- Step 2Clinical briefing
KPCIRC reviews the finding in the context of your treatment.
- Step 3Next options
The engine surfaces evidence-based choices: switch, combine or trial.
- Step 4Seamless transition
Your navigator helps you move to the next line without delay.
03
Why it needs a baseline
Tracking works best against a molecular fingerprint. A baseline profile, for example Signature STb O at 118 genes, establishes what to follow, so later draws can be compared meaningfully.
Being clear about our limits
What we do and do not do
What we DO
- Track whether active treatment is working over time
- Catch resistance and molecular progression early
- Trigger KPCIRC review and a timely next-line plan
- Match cadence to need through Track 2, 4 or 6
What we DON’T do
- Diagnose or switch therapy on its own, KPCIRC decides
- Detect every change, since some tumours shed little ctDNA
- Replace your scans and oncologist review
- Guarantee that an earlier switch will change the outcome
Plain-language glossary (5 terms)
| Term | What it means |
|---|---|
| ctDNA | Circulating tumour DNA, tumour fragments a blood test can read over time. |
| Resistance mutation | A new change that lets a cancer escape a treatment that was working. |
| Molecular progression | A rise in ctDNA signalling the cancer is advancing. |
| VAF | Variant allele frequency, how much of a mutation is present, tracked over time. |
| Serial monitoring | Repeat testing at intervals to watch the trend, not one snapshot. |
Important information and regulatory status
Sentinel Solid is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner (CAP-accredited, ISO 15189) following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal